AstraZeneca PLC (AZN)vsCoherus BioSciences Inc (CHRS)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CHRS
Coherus BioSciences Inc
$1.74
-1.69%
HEALTHCARE · Cap: $262.31M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 139184% more annual revenue ($58.74B vs $42.17M). CHRS leads profitability with a 398.4% profit margin vs 17.4%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CHRS
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for CHRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 33 in profit
Keeps 398 of every $100 in revenue as profit
Revenue surging 64.9% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Earnings declined 75.5%
Negative free cash flow — burning cash
Operating margin of -339.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CHRS
The strongest argument for CHRS centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 398.4% and operating margin at -339.5%. Revenue growth of 64.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CHRS
The primary concerns for CHRS are Market Cap, EPS Growth, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a value stock while CHRS is a growth play — different risk/reward profiles.
CHRS carries more volatility with a beta of 1.04 — expect wider price swings.
CHRS is growing revenue faster at 64.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 47/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Coherus BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?